From Medicineworld.org: Hormone Therapy Goes On Trial
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
Hormone Therapy Goes On Trial
Marcelle Cedars, MDScientists at UCSF Medical Center are about to embark on a study with a controversial theme: Despite its bad reputation at present, can hormone treatment (HT) after menopause protect women from heart disease.
"Heart disease is still the nation's leading killer of women, and we need to understand how the disease develops in women," said lead investigator Marcelle Cedars, MD, director of the Division of Reproductive Endocrinology in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences.
UCSF is one of eight centers nationwide participating in the Kronos Early Estrogen Prevention Study, known as KEEPS, which is being by coordinated by the Phoenix-based Kronos Longevity Research Institute.
UCSF is recruiting 90 healthy, recently menopausal women who have not had a hysterectomy, are six months to three years from their last menses, and are 42 to 58 years of age.
KEEPS is a randomized, placebo-controlled, double-blind trial of 720 women designed to provide prospective data on the risks and benefits of HT in women who have recently begun menopause. Of particular interest is the role of estrogen during menses as it relates to the progression of atherosclerosis (hardening of the arteries).
Previous to 2002, most studies suggested that HT reduced the risk of heart disease by 30 to 50 percent. But in July of that year, the widely published Women's Health Initiative (WHI) was halted by the National Institutes of Health when results showed no preventive benefit against heart disease in women who were a number of years past menopause. The WHI was a primary prevention trial of estrogen plus progestin hormone treatment in 16,608 postmenopausal women between the ages 50-79. It was the first randomized, placebo-controlled, double-blind trial of HT, and for this reason its results were believed to be nearly definitive, according to Cedars.
"Curiously, though, findings from earlier research suggest that hormone treatment may help prevent the early stages of heart attack's precursor, atherosclerosis," said Cedars. HT appears to be ineffective, however -- or may even be harmful -- once the disease is established, she added.
Knowing this, scientists hypothesized that the safety and efficacy of HT depends on exactly how and when it is delivered. They decided to study the risks and benefits of HT on a younger subset of women who recently entered menopause.
KEEPS will address questions left unanswered by the WHI trial, such as: the effectiveness of starting HT in women within three years after the last menstrual period to protect against atherosclerosis and the effectiveness of taking a lower dosage of oral estrogen or wearing a transdermal estradiol (estrogen) patch, as well at HT's effect in improving women's quality of life.
The eight KEEPS study centers are:
* Albert Einstein College of Medicine/Montefiore Medical Center (New York City, NY) * Columbia University College of Physicians and Surgeons (New York City, NY) * Harvard Medical School/Brigham and Women's Hospital (Boston, MA) * Mayo Clinic College of Medicine (Rochester, MN) * University of California, San Francisco Medical Center (San Francisco, CA) * University of Utah School of Medicine (Salt Lake City, UT) * University of Washington School of Medicine/VA Puget Sound Health Care System (Seattle/Tacoma, WA) * Yale University School of Medicine (New Haven, CT).
Women interested in participating in the study at UCSF should contact Nancy Jancar, RN, project director at (415) 353-4300 or email@example.com. Further information on KEEPS is available online at Keep Study .
UCSF is a leading university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care.
Source: University of California, San Francisco
Did you know?
Scientists at UCSF Medical Center are about to embark on a study with a controversial theme: Despite its bad reputation at present, can hormone treatment (HT) after menopause protect women from heart disease. "Heart disease is still the nation's leading killer of women, and we need to understand how the disease develops in women," said lead investigator Marcelle Cedars, MD, director of the Division of Reproductive Endocrinology in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences.
Medicineworld.org: Hormone Therapy Goes On Trial
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.